BR112016003293A2 - anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos - Google Patents

anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos

Info

Publication number
BR112016003293A2
BR112016003293A2 BR112016003293A BR112016003293A BR112016003293A2 BR 112016003293 A2 BR112016003293 A2 BR 112016003293A2 BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A2 BR112016003293 A2 BR 112016003293A2
Authority
BR
Brazil
Prior art keywords
rheumatoid arthritis
neutralizing antibodies
treatment
csf neutralizing
analgesics
Prior art date
Application number
BR112016003293A
Other languages
English (en)
Other versions
BR112016003293A8 (pt
Inventor
Carlsson Malin
Staum Kaltoft Margit
Wagner Thomas
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of BR112016003293A2 publication Critical patent/BR112016003293A2/pt
Publication of BR112016003293A8 publication Critical patent/BR112016003293A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a anticorpos neutralizantes de gm-csf e composições compreendendo os mesmos para uso no tratamento de desordens inflamatórias, tais como artrite reumatoide de acordo com regime de dosagem específico. a invenção refere-se também a anticorpos neutralizantes de gm-csf e composições compreendendo os mesmos para uso no tratamento da dor, por exemplo, dor experimentada nas desordens inflamatórias, tais como artrite reumatoide, de acordo com o regime de dosagem específica.
BR112016003293A 2013-08-30 2014-09-01 Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos BR112016003293A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871900P 2013-08-30 2013-08-30
US201361871904P 2013-08-30 2013-08-30
PCT/EP2014/068489 WO2015028657A1 (en) 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Publications (2)

Publication Number Publication Date
BR112016003293A2 true BR112016003293A2 (pt) 2017-11-21
BR112016003293A8 BR112016003293A8 (pt) 2022-08-16

Family

ID=51454704

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003293A BR112016003293A8 (pt) 2013-08-30 2014-09-01 Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos

Country Status (12)

Country Link
US (2) US10745475B2 (pt)
EP (2) EP3889178A1 (pt)
JP (4) JP2016536327A (pt)
KR (3) KR20220045064A (pt)
CN (2) CN118178647A (pt)
AU (3) AU2014314053C1 (pt)
BR (1) BR112016003293A8 (pt)
CA (1) CA2922251C (pt)
ES (1) ES2860480T3 (pt)
MX (2) MX2016002177A (pt)
RU (1) RU2714919C2 (pt)
WO (1) WO2015028657A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060022659A (ko) 2003-05-15 2006-03-10 디엠아이 바이오사이언시스, 인크 T-세포 매개성 질환의 치료 방법
US8980834B2 (en) 2011-10-10 2015-03-17 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
RU2020136589A (ru) 2014-08-18 2020-12-24 Ампио Фармасьютикалз, Инк. Лечение дегенеративных заболеваний суставов
EP3310375A4 (en) * 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES
UA126565C2 (uk) 2016-09-19 2022-11-02 Ай-Маб Байофарма (Ханчжоу) Ко., Лтд. Антитіло до гм-ксф
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CA3051865C (en) 2017-02-01 2023-01-17 Yale University Treatment of diuretic resistance
SG11202006157VA (en) * 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
WO2019178379A2 (en) * 2018-03-14 2019-09-19 Indiana University Research And Technology Corporation Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS59147297A (ja) 1983-02-10 1984-08-23 株式会社日立製作所 原子炉圧力容器の耐震構造
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3583880D1 (de) 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
BR0108499A (pt) 2000-02-14 2003-03-11 Mitsubishi Pharma Corp Agente terapêutico para hepatite c
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
ATE509032T1 (de) 2002-02-13 2011-05-15 Ludwig Inst For Cancer Res Ltd Chimerizierte gm-csf antikörper
DE60322513D1 (de) 2002-02-27 2008-09-11 Immunex Corp Stabilisierte TNFR-Fc Formulierung mit Arginin
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
CN101824088B (zh) 2002-10-30 2012-05-30 健泰科生物技术公司 Il-17产生的抑制
CA2562771C (en) 2004-04-12 2013-04-09 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20070095949A (ko) 2004-12-16 2007-10-01 제넨테크, 인크. 자가면역 장애의 치료 방법
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2458071C2 (ru) 2005-04-18 2012-08-10 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
HUE058876T2 (hu) 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン,エルエルシー タンパク質製剤
CN101501070B (zh) 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
DK2423229T3 (da) 2006-03-27 2013-08-05 Medimmune Ltd Bindingselement til GM-CSF-receptor
MX2009005398A (es) * 2006-11-21 2009-08-20 Kalobios Pharmaceuticals Inc Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
JP5513380B2 (ja) 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合剤の組成物
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
MX2010005291A (es) 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
CN102037016B (zh) 2008-04-28 2015-06-03 卡罗拜奥斯制药公司 针对粒细胞巨噬细胞集落刺激因子的抗体
EA024654B1 (ru) 2008-04-29 2016-10-31 Эмджен Рисерч (Мьюник) Гмбх Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
KR20140064943A (ko) 2009-05-05 2014-05-28 모르포시스 아게 다발성 경화증의 치료
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
CA2783715A1 (en) 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
US20140335081A1 (en) 2011-10-10 2014-11-13 Medlmmune Limited Treatment For Rheumatoid Arthritis
KR20240091288A (ko) 2012-09-20 2024-06-21 모르포시스 아게 류마티스 관절염에 대한 치료
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
JP6346389B1 (ja) 2016-08-03 2018-06-20 古河電気工業株式会社 金属粒子含有組成物

Also Published As

Publication number Publication date
AU2023210647A1 (en) 2023-10-12
CA2922251C (en) 2023-10-17
JP2016536327A (ja) 2016-11-24
CN118178647A (zh) 2024-06-14
US20210171620A1 (en) 2021-06-10
KR20160044035A (ko) 2016-04-22
EP3889178A1 (en) 2021-10-06
AU2014314053B2 (en) 2020-03-12
MX2021010472A (es) 2021-10-01
JP2024123249A (ja) 2024-09-10
US20160355584A1 (en) 2016-12-08
RU2714919C2 (ru) 2020-02-21
JP2020109108A (ja) 2020-07-16
EP3039039B1 (en) 2021-03-10
EP3039039A1 (en) 2016-07-06
WO2015028657A1 (en) 2015-03-05
BR112016003293A8 (pt) 2022-08-16
US10745475B2 (en) 2020-08-18
MX2016002177A (es) 2016-06-28
RU2016109944A (ru) 2017-10-06
AU2014314053C1 (en) 2023-11-02
AU2014314053A1 (en) 2016-02-11
ES2860480T3 (es) 2021-10-05
CN105705518A (zh) 2016-06-22
RU2016109944A3 (pt) 2018-07-09
JP2022105160A (ja) 2022-07-12
KR20220045064A (ko) 2022-04-12
US11795216B2 (en) 2023-10-24
CA2922251A1 (en) 2015-03-05
KR20240090993A (ko) 2024-06-21
AU2020203917A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
BR112016003293A2 (pt) anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112015022597A2 (pt) partículas modificadoras da imunidade para o tratamento de inflamação
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112016019176A2 (pt) anticorpos il-21
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
TN2016000057A1 (en) Methods of treating sporadic inclusion body myositis
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
BR112012005957A2 (pt) compostos tricíclicos e usos farmacêuticos dos mesmos
BR112017008045A2 (pt) compostos como inibidores de nik
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2014013678A (es) Agentes para neutralizacion de influenza.
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
NI201600070A (es) Inhibidores tetracíclicos de autotaxina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.